Why Obesity Drug Weight Loss Doesn't Last
New obesity drugs offer transformative weight loss initially, but maintaining results is challenging due to biological and behavioral factors.
Category : Search result: obesity reduction drugs
Waist-to-Height Ratio Better Than BMI for Obesity
New research finds the waist-to-height ratio is a simpler, more effective indicator of obesity risks than BMI, especially for children. Learn why this metric matters for public health in India.
Study: Weight returns fast after stopping obesity drugs
New research shows stopping weight loss drugs like semaglutide leads to rapid weight regain. Experts suggest long-term strategies for obesity management in India.
Oprah Winfrey Opens Up on Weight Struggle & Medical Truth
Oprah Winfrey reveals her decades-long weight struggle, debunking obesity as a moral failing. She credits medical science and a genetic 'set point' for her newfound freedom. Read her inspiring journey.
Tarn Taran's Second Phase of War Against Drugs Begins
Tarn Taran police intensify the war on drugs with Phase 2. SSP Ranjit Singh leads a major crackdown, seizing assets and arresting peddlers. Read the full strategy.
Trump on weight-loss drugs: 'No, I have not. I probably should.'
In a NYT interview, Donald Trump revealed he hasn't used GLP-1 drugs like Ozempic, sparking debate on obesity, healthcare costs, and his administration's drug price policies. Read the full story.
AIIMS Delhi Starts Free Drug Monitoring for Epilepsy
AIIMS New Delhi now provides free Therapeutic Drug Monitoring for epilepsy patients, eliminating costly private lab fees. Learn how this improves treatment and saves money.
Novo Nordisk: Wegovy Price Cut to Boost India Obesity Therapy 5-7x
Novo Nordisk expects India's obesity drug market to grow rapidly after a 37% Wegovy price cut, mirroring insulin uptake. Generic competition looms with a Rs 5000-crore opportunity.
Weight-loss drugs poised for takeoff, cancer care expands in 2026
GLP-1 weight-loss drugs, despite limited uptake, topped India's pharma sales by value in 2025. With generics and new approvals coming, 2026 promises wider access. Plus, government plans 200+ Day Care Cancer Centres. Read the full analysis.
Indian Pharma Firms Eye Licensing Deals for Obesity Drugs
As patents expire, Indian drugmakers like Lupin and Ajanta Pharma are forging licensing and distribution deals for GLP-1 obesity drugs. The market is set for explosive growth. Explore the key partnerships and market dynamics.
Weight-Loss Pill Race in 2026: Lilly Leads Novo Nordisk
Novo Nordisk and Eli Lilly to launch oral GLP-1 drugs in 2026. Despite Novo's head start, analysts predict Lilly's market leadership in obesity and diabetes treatments will persist for years. Explore the details.
Hidden Causes of Dog Weight Gain & Breeds Most at Risk
Discover how daily treats and scraps cause dog obesity. Learn which breeds like Pugs & Labradors are prone and how to manage your pet's weight effectively.
2025: The Year Weight-Loss Drugs Redefined Health in India
Explore how 2025's weight-loss drug boom in India shifted focus from fitness to thinness, raising concerns about medicalisation, side effects, and societal pressure. Read the full analysis.
New Study: 75% US Adults May Be Obese, Not 40%
A new study reveals over 75% of US adults may have obesity under new waist-based criteria, nearly double the BMI estimate. Researchers urge updated screening methods.
Bengaluru engineer arrested for making drugs at home
A Bengaluru software engineer was arrested for allegedly manufacturing synthetic drugs like MDMA in a makeshift home laboratory. Police seized drugs worth lakhs and equipment. Read the shocking details.
Avadi Sees Major Drop in Crime, Murders Down 21% in 2025
Avadi city police report a significant decline in violent and property crimes in 2025. Murders fell 21%, chain-snatching 35%, aided by NAFIS tech and strategic policing. Read the full report.
DCA Raids Quack's Clinic, Seizes Illegal Drugs Worth ₹15,011
Drugs Control Administration officials raided an unlicensed clinic in Karimnagar, seizing illegal steroids and antibiotics. The crackdown highlights the public health risks of unauthorized drug sales. Read more.
India's Childhood Obesity Crisis: NFHS Data Shows Alarming Rise
Childhood obesity in India has skyrocketed, with a 288% increase among boys. WHO warns 188 million kids globally will be obese by 2025. Learn the causes, health risks, and prevention strategies.
India's Weight-Loss Drug Market to Grow 10x by 2030
Explore the social and economic impact of GLP-1 drugs like Ozempic & Mounjaro in India. A ₹1,000 crore market is poised for massive growth. Share your thoughts.
Ozempic, Wegovy Reduce Food Spending, New Study Finds
New research reveals GLP-1 weight-loss drugs like Ozempic significantly cut grocery and restaurant spending. Discover the impact on food habits in India and globally.
Obesity Drug Market in India Grows 10-Fold in 5 Years
India's anti-obesity market, now valued at over Rs 1,000 crore, is poised for explosive growth with new drugs and generics. Discover how AI and GLP-1 therapies are transforming healthcare.
New Obesity Drugs Target Cell Energy Production
Scientists develop novel experimental drugs for obesity by targeting mitochondrial energy production in cells, offering a potential new treatment pathway. Learn about this breakthrough research.
Teen's liver transplant warns of fatty liver disease risk
A 14-year-old from Surat needed a liver transplant due to advanced fatty liver disease, accelerated by junk food and genetic risk. Hepatologists urge urgent action on childhood obesity and diet.
Sleep, Stress, Belly Fat Drive India's Breast Cancer Surge
ICMR study reveals disrupted sleep, chronic stress, and central obesity are key drivers of India's rising breast cancer burden, projected to add 50,000 cases yearly. Learn the risk factors.
First Weight-Loss Pill Approved in US, Priced $149/Month
US FDA approves Novo Nordisk's Wegovy Pill, first oral GLP-1 drug for weight loss. Priced at $149/month, it promises wider access and challenges injectable dominance. Read more.
GLP-1 Drugs Show Benefits Beyond Weight Loss
New research reveals GLP-1 drugs like semaglutide offer significant heart, liver, and kidney benefits, transforming treatment for obesity-related conditions. Discover the full scope of their impact.
Emcure Enters Obesity Market with Novo Nordisk's Semaglutide
Emcure Pharmaceuticals launches Poviztra, a weekly semaglutide injection for weight loss, in partnership with Novo Nordisk. Priced from ₹2,200 per week, it targets India's massive obesity market.
Why Stopping Weight-Loss Jabs Feels Like 'Jumping Off a Cliff'
Women share harrowing experiences of stopping anti-obesity drugs like Wegovy. Experts warn 60-80% weight returns without a plan. Learn about the side effects and new drugs in India.
Lack of Drug Inspectors Hampers Action on Spurious Drugs
A severe shortage of drug inspectors is hampering enforcement against spurious and adulterated medicines in India. Officials admit the staffing crisis is a major hurdle. Read more on the critical public health issue.
146 Punjab College Teachers Trained in Anti-Drug Drive
Punjab trains 146 teachers as nodal officers to combat drug abuse in colleges. Workshops under NAPDDR focus on mental health, stigma, and support. #DrugFreePunjab
Page 1 of 4